-
Je něco špatně v tomto záznamu ?
Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review
E. Laukhtina, R. Sari Motlagh, K. Mori, F. Quhal, VM. Schuettfort, H. Mostafaei, S. Katayama, NC. Grossmann, G. Ploussard, PI. Karakiewicz, A. Briganti, M. Abufaraj, D. Enikeev, B. Pradere, SF. Shariat
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, systematický přehled
- MeSH
- čas zasáhnout při rozvinutí nemoci * MeSH
- lidé MeSH
- míra přežití MeSH
- nádory prostaty mortalita patologie chirurgie MeSH
- prostatektomie * MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- systematický přehled MeSH
PURPOSE: To summarize the available evidence on the survival and pathologic outcomes after deferred radical prostatectomy (RP) in men with intermediate- and high-risk prostate cancer (PCa). METHODS: The PubMed database and Web of Science were searched in November 2020 according to the PRISMA statement. Studies were deemed eligible if they reported the survival and pathologic outcomes of patients treated with deferred RP for intermediate- and high-risk PCa compared to the control group including those patients treated with RP without delay. RESULTS: Overall, nineteen studies met our eligibility criteria. We found a significant heterogeneity across the studies in terms of definitions for delay and outcomes, as well as in patients' baseline clinicopathologic features. According to the currently available literature, deferred RP does not seem to affect oncological survival outcomes, such as prostate cancer-specific mortality and metastasis-free survival, in patients with intermediate- or high-risk PCa. However, the impact of deferred RP on biochemical recurrence rates remains controversial. There is no clear association of deferring RP with any of the features of aggressive disease such as pathologic upgrading, upstaging, positive surgical margins, extracapsular extension, seminal vesicle invasion, and lymph node invasion. Deferred RP was not associated with the need for secondary treatments. CONCLUSIONS: Owing to the different definitions of a delayed RP, it is hard to make a consensus regarding the safe delay time. However, the current data suggest that deferring RP in patients with intermediate- and high-risk PCa for at least around 3 months is generally safe, as it does not lead to adverse pathologic outcomes, biochemical recurrence, the need for secondary therapy, or worse oncological survival outcomes.
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology King Fahad Specialist Hospital Dammam Saudi Arabia
Department of Urology La Croix du Sud Hospital Quint Fonsegrives Toulouse France
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology University Hospital Zurich Zurich Switzerland
Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Vita Salute San Raffaele University Milan Italy
Department of Urology Weill Cornell Medical College New York NY USA
European Association of Urology Research Foundation Arnhem Netherlands
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Research Center for Evidence Based Medicine Tabriz University of Medical Sciences Tabriz Iran
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22003376
- 003
- CZ-PrNML
- 005
- 20220127150309.0
- 007
- ta
- 008
- 220113s2021 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00345-021-03703-8 $2 doi
- 035 __
- $a (PubMed)34047825
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
- 245 10
- $a Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review / $c E. Laukhtina, R. Sari Motlagh, K. Mori, F. Quhal, VM. Schuettfort, H. Mostafaei, S. Katayama, NC. Grossmann, G. Ploussard, PI. Karakiewicz, A. Briganti, M. Abufaraj, D. Enikeev, B. Pradere, SF. Shariat
- 520 9_
- $a PURPOSE: To summarize the available evidence on the survival and pathologic outcomes after deferred radical prostatectomy (RP) in men with intermediate- and high-risk prostate cancer (PCa). METHODS: The PubMed database and Web of Science were searched in November 2020 according to the PRISMA statement. Studies were deemed eligible if they reported the survival and pathologic outcomes of patients treated with deferred RP for intermediate- and high-risk PCa compared to the control group including those patients treated with RP without delay. RESULTS: Overall, nineteen studies met our eligibility criteria. We found a significant heterogeneity across the studies in terms of definitions for delay and outcomes, as well as in patients' baseline clinicopathologic features. According to the currently available literature, deferred RP does not seem to affect oncological survival outcomes, such as prostate cancer-specific mortality and metastasis-free survival, in patients with intermediate- or high-risk PCa. However, the impact of deferred RP on biochemical recurrence rates remains controversial. There is no clear association of deferring RP with any of the features of aggressive disease such as pathologic upgrading, upstaging, positive surgical margins, extracapsular extension, seminal vesicle invasion, and lymph node invasion. Deferred RP was not associated with the need for secondary treatments. CONCLUSIONS: Owing to the different definitions of a delayed RP, it is hard to make a consensus regarding the safe delay time. However, the current data suggest that deferring RP in patients with intermediate- and high-risk PCa for at least around 3 months is generally safe, as it does not lead to adverse pathologic outcomes, biochemical recurrence, the need for secondary therapy, or worse oncological survival outcomes.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a prostatektomie $7 D011468
- 650 _2
- $a nádory prostaty $x mortalita $x patologie $x chirurgie $7 D011471
- 650 _2
- $a míra přežití $7 D015996
- 650 12
- $a čas zasáhnout při rozvinutí nemoci $7 D061665
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a Sari Motlagh, Reza $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- 700 1_
- $a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
- 700 1_
- $a Schuettfort, Victor M $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Mostafaei, Hadi $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
- 700 1_
- $a Katayama, Satoshi $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
- 700 1_
- $a Grossmann, Nico C $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, University Hospital Zurich, Zurich, Switzerland
- 700 1_
- $a Ploussard, Guillaume $u Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, Toulouse, France
- 700 1_
- $a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada
- 700 1_
- $a Briganti, Alberto $u Department of Urology, Vita Salute San Raffaele University, Milan, Italy
- 700 1_
- $a Abufaraj, Mohammad $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
- 700 1_
- $a Enikeev, Dmitry $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. shahrokh.shariat@meduniwien.ac.at $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac.at $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u European Association of Urology Research Foundation, Arnhem, Netherlands. shahrokh.shariat@meduniwien.ac.at
- 773 0_
- $w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 39, č. 11 (2021), s. 4085-4099
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34047825 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127150306 $b ABA008
- 999 __
- $a ok $b bmc $g 1750980 $s 1154525
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 39 $c 11 $d 4085-4099 $e 20210528 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
- LZP __
- $a Pubmed-20220113
